{"nctId":"NCT00245050","briefTitle":"Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer","startDateStruct":{"date":"2004-04"},"conditions":["Breast Cancer","Drug/Agent Toxicity by Tissue/Organ","Endometrial Cancer","Fallopian Tube Cancer","Ovarian Cancer","Peritoneal Cavity Cancer"],"count":34,"armGroups":[{"label":"Pyridoxine","type":"EXPERIMENTAL","interventionNames":["Dietary Supplement: pyridoxine hydrochloride","Drug: doxorubicin HCL liposome"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: doxorubicin HCL liposome"]}],"interventions":[{"name":"pyridoxine hydrochloride","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"doxorubicin HCL liposome","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Diagnosis of 1 of the following:\n\n  * Recurrent ovarian, fallopian tube, or peritoneal cavity cancer\n  * Metastatic breast cancer\n  * Advanced endometrial cancer\n* Planning to receive chemotherapy with doxorubicin HCl liposome at a dose of 40 mg/m\\^2\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nSex\n\n* Not specified\n\nMenopausal status:\n\n* Not specified\n\nPerformance status\n\n* Karnofsky 60-100%\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Absolute neutrophil count ≥ 1,500/mm\\^3\n* Platelet count ≥ 100,000/mm\\^3\n* Hemoglobin ≥ 9.0 g/dL\n\nHepatic\n\n* AST and ALT ≤ 2 times upper limit of normal (ULN)\n* Alkaline phosphatase ≤ 2 times ULN\n* Bilirubin normal\n\nRenal\n\n* Creatinine ≤ 2.0 mg/dL\n\nCardiovascular\n\n* Ejection fraction ≥ 50% by MUGA or 2-D echocardiogram\n* No history of cardiac disease\n* No New York Heart Association class II-IV heart disease\n* No clinical evidence of congestive heart failure\n\nOther\n\n* Not pregnant or nursing\n* Fertile patients must use effective contraception during and for 3 months after completion of study treatment\n* No active infection requiring antibiotics\n* No history of hypersensitivity reaction attributed to a conventional formulation of doxorubicin HCl or doxorubicin HCl liposome and any of its components\n* No other invasive malignancy within the past 5 years except nonmelanoma or basal cell skin cancer\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* At least 3 weeks since prior biologic or immunologic agents for this cancer\n\nChemotherapy\n\n* Recovered from prior chemotherapy\n\n  * Alopecia or neuropathy allowed\n* No prior doxorubicin HCl liposome\n* Other concurrent chemotherapy allowed provided palmar-plantar erythrodysesthesia is not one of the side effects of the therapy\n\n  * No concurrent cytarabine, fluorouracil, liposomal daunorubicin, or capecitabine\n  * No concurrent pre-medication with corticosteroids as part of the chemotherapy regimen\n\nEndocrine therapy\n\n* See Chemotherapy\n* At least 3 weeks since prior and no concurrent oral or topical corticosteroids\n* At least 1 week since prior hormonal therapy for this cancer\n\n  * Concurrent hormone replacement therapy allowed\n\nRadiotherapy\n\n* At least 3 weeks since prior radiotherapy for this cancer and recovered\n\nSurgery\n\n* Recovered from prior surgery\n\nOther\n\n* At least 3 weeks since prior and no other concurrent forms of pyridoxine except what is included in a multivitamin\n* No prior anticancer treatment that contraindicates study treatment\n* No concurrent amifostine or other protective agents","healthyVolunteers":false,"sex":"FEMALE","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Palmar-plantar Erythrodysesthesia (PPE)","description":"Patients were monitored weekly with phone calls from the research nurse and monthly at clinic visits for overall (including pyridoxine) and specific doxorubicin HCl liposome related toxicities using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life (QOL) as Measured by Functional Assessment of Cancer Therapy (FACT-G)","description":"QOL was measured with the FACT-G questionnaire following the third course of doxorubicin HCl liposome before the patient was seen by the treating physician and before chemotherapy was administered. The FACT-G, version 4, is a 27-item core questionnaire evaluating the domains of physical, functional, family-social, and emotional well-being (PWB, FWB, SWB, EWB). Total score ranges from 0-108 and higher scores indicate better QOL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.9","spread":"10.2"},{"groupId":"OG001","value":"84.4","spread":"9.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":15},"commonTop":["Blood/bone marrow","Gastrointestinal","Constitutional symptoms","Pain","Pulmonary/upper respiratory"]}}}